NCT03539744: Phase 3 - A Study of Venetoclax/Dex Compared With Pomalidomide/Dex - t(11;14) +ive RRMM
Updated: Feb 10
CANOVA TRIAL
t(11;14)-positive Relapsed or Refractory Multiple Myeloma.
A Study of Venetoclax and Dexamethasone Compared With Pomalidomide and Dexamethasone in Participants With Relapsed or Refractory Multiple Myeloma
A study designed to evaluate the safety and efficacy of venetoclax plus dexamethasone (VenDex) compared with pomalidomide plus dexamethasone (PomDex) in participants with t(11;14)-positive Relapsed or Refractory Multiple Myeloma.
Sponsor
AbbVie
Collaborator
Roche-Genentech
Multiple locations
International Study
ClinicalTrials.gov Identifier: NCT03539744
Official Title: A Phase 3, Multicenter, Randomized, Open Label Study of Venetoclax and Dexamethasone Compared With Pomalidomide and Dexamethasone in Subjects With t(11;14)-Positive Relapsed or Refractory Multiple Myeloma
First Posted : May 29, 2018
Click here for details on ClinicalTrials.gov
Drug: Pomalidomide
Drug: Dexamethasone
Drug: Venetoclax
Locations
United States, Arizona
United States, California
United States, Colorado
United States, Florida
United States, Kentucky
United States, Maryland
United States, Massachusetts
United States, Michigan
United States, Minnesota
United States, New York
United States, Ohio
United States, Pennsylvania
United States, Texas
United States, Utah
United States, Washington
Australia, New South Wales
Australia, Queensland
Australia, South Australia
Australia, Western Australia
Canada, Alberta
Canada, British Columbia
Canada, Nova Scotia
Canada, Quebec
China
China, Beijing
China, Guangdong
China, Henan
China, Hubei
China, Jiangsu
China, Jiangxi
China, Liaoning
China, Shanghai
China, Tianjin
China, Zhejiang
Europe
United Kingdom
France
Germany
Italy
Spain
Czechia
Denmark
Greece
Sweden
Turkey
Ukraine
Asia
Israel
Japan
Korea, Republic of
Russian Federation
Singapore